1Yussoff Dawood M.Nonsteroidal anti-inflammatory drugs and reproduction.Am J Obstet Gynecol,1993,169:1255-1265.
2Takahashi Y,Roman C,Chemtob S,et al.Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo.Am J Physiol Regulatory Integrative Comp Physiol,2000,278:R1496-R1505.
4Petri M.Immunosuppressive drug use in pregnancy.Autoimmunity,2003,36:51.
5Costedoat-Chalumeau N,Amoura Z,Duhaut P,et al:Safety of hydroxycholoroquine in pregnant patients with connective tissue disease.Arthritis Rheum,2003,48:3207-3214.
6Motta M,Tincani A.Antimalarial agents in pregnancy.Lancet,2002,359:524-525.
7Kremer JM.Toward a better understanding of methotrexate.Arthritis Rheum,2004,50:1370-1382.
8Brent RL.Teratogen update:reproductive risks of leflunomide (Arava):a pyrimidine synthesis inhibitor:counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child.Teratology,2001,63:106-112.
9Committee on Drugs.American Academy of Pediatrics:the transfer of drugs and other chemicals into human milk.Pediatrics,1994,93:137-150.
10Moskovitz DN,Bodian C,Chapman ML,et al.The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients.Am J Gastroenterol,2004,99:656-661.
二级参考文献6
1Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of diffuse proliferative lupus nephritis : a meta-analysis of randomized controlled trials. Am J Kidney Dis,2004,43:197-208.
2Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum,1982,25 : 1271-1277.
3Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. a disease activity index for lupus patients. Arthritis Rheum, 1992,35:630-640.
4Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythmatosus receiving cyclophosphamide therapy. Arthritis Rheum, 1998,41:831-837.
5Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum, 1999,42 : 1274-1280.
6Krening CF, Rehling-Anthony K, Garko C. Oxytocin admin- istration: the transition to a safer model of care. J Perinot Neonat Nur, 2012,26(1) :15-24.
7Murphy DJ,Carey M, Montgomery AA, et al. Study proto- col. ECSSIT-Elective Caesarean Section Syntocinon infusion Trial. A multi-centre randomised controlled trial of oxytocin (Syntocinon ) 5IU bolus and placebo infusion versus oxyto- cin 5 IU bolus and 40 IU infusion for the control of blood loss at elective caesarean section. BMC Pregnancy Childbirth, 2009,9(11) : 10-36.
8Hsu MM,Chou YY,Chang YC, et al. An analysis of excitato ry amino acids, nitric oxide, and prostaglandin E2 in the cere- brospinal fluid of pregnant women: the effect on labor pain. Anesth Analg, 2001,93(5) : 1293-1296.
9Deussen AR, Ashwood P, Martis R. Analgesia for relief of pain due to uterine cramping/involution after birth. 2011,11 (5) : CD004908.
10Hsu HW, Cheng YJ, Chen LK, et al. Differential analgesic effect of tenoxicam on the wound pain and uterine cramping pain after cesarean section. Clin J Pain, 2003,19 (1) : 55-58.
